Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Low dose |
| 2 | EXPERIMENTAL | Middle dose |
| 3 | EXPERIMENTAL | High dose |
| 4 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen | BIOLOGICAL | Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8 |
| Hepatitis B Vaccine (Recombinant) | BIOLOGICAL | IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24 |
Inclusion Criteria: * Willing and able to give written informed consent * Progressive loss of kidney function with more advanced stage 3 (GFR at least 45 mL/min) or stage 4 chronic kidney disease by National Kidney Foundation classification, and are expected to eventually go on hemodialysis * Body ...